Biolinerx Ltd ADR (BLRX) Stock Price, Quote & News

Company Profile

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous...

Industry: Biotechnology

Sector: Healthcare

Phone: 972 8 642 9100

Fax: 972 8 642 9101

Website: www.biolinerx.com

Address:

Modi’in Technology Park, 2 HaMa’ayan Street, Hevel Modi'in, Israel

gargoyl Feb. 9 at 8:10 PM

$VSTM $BLRX Boxed them 👇🏼

0 · Reply

gargoyl Feb. 9 at 7:50 PM

$BLRX new pivot lived up to 3.82 This week 🎯 $REGN $PFE $BMY Target 🎯 $18 Long the 🦋 Phil’s 🥷 the ninja

0 · Reply

gargoyl Feb. 9 at 6:35 PM

$BLRX 👀 my little brother just popped his head into my trading room, he sees things , patterns, algo models, trends , fake outs, spoofs , volume, relationships, relative strength, flows etc.. he says this is on verge of an explosion up .. he doesn’t even know the value or growth possibility in cancer TAM or pipeline legitimacy, or even the three partnerships or the collaborations , let alone the numerous catalysts before this approaching ER .. He is 13yr old , a numbers person. Target 🎯 $18 this year $XBI $VSTM Phil the 🥷 Long the 🦋

0 · Reply

rangeyuri Feb. 9 at 11:06 AM

$BLRX is a commercial-stage oncology biotech; its challenge is market penetration against entrenched competitors and combination therapies, requiring a large commercial infrastructure or a lucrative partnership.

1 · Reply

DiaJay Feb. 6 at 4:42 PM

$BLRX This stock is such a scam.

0 · Reply

PeelonDusk Feb. 6 at 4:30 PM

$BLRX Been a while. How are things going. This used to be a pumper.

0 · Reply

gargoyl Feb. 4 at 5:35 PM

$BLRX focus 🧘 on the new trend. MM can’t hold this down much longer, one or more of the many catalysts are immanent. ER.. Generally, it’s almost impossible to predict when MM flips the manipulation on their books but this book is reaching that point, RSI shows an increasing coil up. That’s the chart , the value and the growth is in the pipeline and the partnerships. Look her up , do DD , winter is leaving, summer is coming strong 💪 Target 🎯 $18 $VSTM 3.4M volume today can’t hold $7 ? , that’s the new pivot 👀 $REGN $XBI

0 · Reply

WallStWireAds Feb. 4 at 7:11 AM

$PPBT $JANX $XLO $BLRX >> After BMS’s $850M Bet on Tumor-Activated Immunotherapy, Investors Are Asking: Who’s Next? https://www.bioreview.com/after-bmss-850m-bet-on-tumor-activated-immunotherapy-investors-are-asking-whos-next/

2 · Reply

TwongStocks Jan. 30 at 5:06 PM

$BLRX The St Jude's Phase 1 trial testing Aphexda as a mobilizer in sickle cell patients was updated. https://clinicaltrials.gov/study/NCT06442761 Changes since last update: • BLRX has been replaced by Ayrmid as a study collaborator. No surprise since Ayrmid now owns the rights to this indication. • Minor change to study procedure. They will collect stem cells in SCD patients 4 hours after injection with Aphexda, instead of waiting 8 hours.

0 · Reply

gargoyl Jan. 30 at 3:18 PM

$BLRX who’s feeling 3.37 today 🥷

0 · Reply

BioLineRx Ltd. (BLRX) Q3 2025 Earnings Call Transcript

Nov 24, 2025, 7:00 AM EST - 2 months ago

BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 18, 2025, 7:00 AM EST - 2 months ago

BioLineRx to Report Third Quarter 2025 Results on November 24, 2025

Nov 17, 2025, 7:00 AM EST - 3 months ago

BioLineRx Announces Receipt of USPTO Notice of Allowance for Key Patent Covering GLIX1 for Treating a Broad Range of Cancer Types

Sep 29, 2025, 3:27 PM EDT - 4 months ago

BioLineRx Ltd. - Special Call

Sep 29, 2025, 7:00 AM EDT - 4 months ago

BioLineRx Ltd. and Hemispherian AS Establish Joint Venture to Develop GLIX1, a First-in-Class, Oral, Small Molecule Targeting DNA Damage Response in Glioblastoma and Other Cancers

Aug 14, 2025, 10:44 AM EDT - 6 months ago

BioLineRx Ltd. (BLRX) Q2 2025 Earnings Call Transcript

Aug 14, 2025, 7:00 AM EDT - 6 months ago

BioLineRx Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 7, 2025, 7:00 AM EDT - 6 months ago

BioLineRx to Report Second Quarter 2025 Results on August 14, 2025

May 30, 2025, 1:58 PM EDT - 9 months ago

Why Is Nano-Cap BioLineRx Stock Surging On Friday?

May 30, 2025, 7:00 AM EDT - 9 months ago

BioLineRx Announces New Pilot Phase Data from Phase 2 Combination Trial of Motixafortide in First-Line Pancreatic Cancer (PDAC) to be Presented at ASCO 2025 Annual Meeting

May 27, 2025, 12:55 PM EDT - 9 months ago

BioLineRx Ltd. (BLRX) Q1 2025 Earnings Call Transcript

May 27, 2025, 7:00 AM EDT - 9 months ago

BioLineRx Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 20, 2025, 7:00 AM EDT - 9 months ago

BioLineRx to Report First Quarter 2025 Results on May 27, 2025

Mar 31, 2025, 10:52 AM EDT - 11 months ago

BioLineRx Ltd. (BLRX) Q4 2024 Earnings Call Transcript

Mar 31, 2025, 7:00 AM EDT - 11 months ago

BioLineRx Reports 2024 Financial Results and Provides Corporate Update

Mar 24, 2025, 7:00 AM EDT - 11 months ago

BioLineRx to Report 2024 Annual Results on March 31, 2025

Jan 21, 2025, 7:00 AM EST - 1 year ago

BioLineRx Issues Letter to Shareholders

Jan 17, 2025, 7:00 AM EST - 1 year ago

BioLineRx Announces Change to Ratio of American Depositary Shares to Ordinary Shares

Jan 6, 2025, 2:01 PM EST - 1 year ago

Nasdaq Surges Over 200 Points; BioLineRx Shares Plummet

Jan 6, 2025, 8:57 AM EST - 1 year ago

BioLineRx Announces $10 Million Registered Direct Offering

Nov 25, 2024, 10:58 AM EST - 1 year ago

BioLineRx Ltd. (BLRX) Q3 2024 Earnings Call Transcript

Nov 25, 2024, 7:00 AM EST - 1 year ago

BioLineRx Reports Third Quarter 2024 Financial Results and Provides Update on Transformation to Drive Shareholder Value

Nov 21, 2024, 6:30 AM EST - 1 year ago

BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA® (motixafortide) through Gamida Cell Ltd.

Nov 20, 2024, 7:19 AM EST - 1 year ago

BioLineRx to Report Third Quarter 2024 Results on November 25, 2024

Nov 5, 2024, 9:00 AM EST - 1 year ago

BioLineRx Announces Oral Presentation on Data from Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease at ASH 2024

Oct 16, 2024, 7:00 AM EDT - 1 year ago

BioLineRx Announces USPTO Allowance of New Composition of Matter Patent on Motixafortide

Sep 17, 2024, 1:01 PM EDT - 1 year ago

BioLineRx Launches 'Mobilization Matters': A Digital Resource for People with Multiple Myeloma Preparing for Stem Cell Collection

Aug 15, 2024, 3:03 PM EDT - 1 year ago

BioLineRx Ltd. (BLRX) Q2 2024 Earnings Call Transcript

Aug 15, 2024, 7:00 AM EDT - 1 year ago

BioLineRx Reports Second Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates

Aug 8, 2024, 7:00 AM EDT - 1 year ago

BioLineRx to Report Second Quarter 2024 Results on August 15, 2024

May 30, 2024, 7:00 AM EDT - 1 year ago

BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applications in Sickle Cell Disease (SCD)

May 28, 2024, 5:56 PM EDT - 1 year ago

BioLineRx Ltd. (BLRX) Q1 2024 Earnings Call Transcript

May 28, 2024, 7:00 AM EDT - 1 year ago

BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates

May 24, 2024, 7:00 AM EDT - 1 year ago

BioLineRx Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting

May 22, 2024, 7:00 AM EDT - 1 year ago

BioLineRx to Report First Quarter 2024 Results on May 28, 2024

May 17, 2024, 5:00 PM EDT - 1 year ago

BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification

May 6, 2024, 7:00 AM EDT - 1 year ago

BioLineRx Announces Poster Presentation on Economic Model Data for APHEXDA® (motixafortide) as part of CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at ISPOR 2024

Apr 17, 2024, 7:00 AM EDT - 1 year ago

BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting

Apr 10, 2024, 7:00 AM EDT - 1 year ago

BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement

Apr 1, 2024, 9:00 AM EDT - 2 years ago

BioLineRx Announces $6 Million Registered Direct Offering

Mar 26, 2024, 11:38 AM EDT - 2 years ago

BioLineRx Ltd. (BLRX) Q4 2023 Earnings Call Transcript

Mar 26, 2024, 7:00 AM EDT - 2 years ago

BioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio Updates

Mar 20, 2024, 7:00 AM EDT - 2 years ago

BioLineRx to Report 2023 Annual Financial Results on March 26, 2024

Mar 6, 2024, 8:00 AM EST - 2 years ago

Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning

CADL IMRX ONCY

Mar 4, 2024, 7:00 AM EST - 2 years ago

BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent Covering Method of Manufacturing Motixafortide (BL-8040) Suitable for Large Scale Production

Feb 28, 2024, 7:00 AM EST - 2 years ago

BioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC)

Feb 16, 2024, 7:00 AM EST - 2 years ago

BioLineRx Announces Acceptance of Two Poster Presentations on APHEXDA® (motixafortide) for CD34+ Hematopoietic Stem Cell (HSC) Mobilization in Patients with Multiple Myeloma at the 2024 Tandem Meetings of ASTCT® and CIBMTR®

Dec 21, 2023, 7:00 AM EST - 2 years ago

BioLineRx Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease

Dec 4, 2023, 6:42 PM EST - 2 years ago

BioLineRx: Still A Buy, With Some Questions

gargoyl Feb. 9 at 8:10 PM

$VSTM $BLRX Boxed them 👇🏼

0 · Reply

gargoyl Feb. 9 at 7:50 PM

$BLRX new pivot lived up to 3.82 This week 🎯 $REGN $PFE $BMY Target 🎯 $18 Long the 🦋 Phil’s 🥷 the ninja

0 · Reply

gargoyl Feb. 9 at 6:35 PM

0 · Reply

rangeyuri Feb. 9 at 11:06 AM

1 · Reply

DiaJay Feb. 6 at 4:42 PM

$BLRX This stock is such a scam.

0 · Reply

PeelonDusk Feb. 6 at 4:30 PM

$BLRX Been a while. How are things going. This used to be a pumper.

0 · Reply

gargoyl Feb. 4 at 5:35 PM

0 · Reply

WallStWireAds Feb. 4 at 7:11 AM

2 · Reply

TwongStocks Jan. 30 at 5:06 PM

0 · Reply

gargoyl Jan. 30 at 3:18 PM

$BLRX who’s feeling 3.37 today 🥷

0 · Reply

gargoyl Jan. 29 at 5:34 PM

$BLRX 🦍 in a new zone here, haven’t seen this level in a while of consolidation, side ways accumulation , the entities belly must be full or filling, now we run 🏃‍♂️…. The simmering is coming to a rolling boil … watch, MM can’t constrain this on volume, manipulation was fun for a while , Watch .. $VSTM 👀

0 · Reply

gargoyl Jan. 29 at 4:39 PM

$VSTM a peek into one “trader” mind .. charts are important, charts show the history of the volume in and out at particular times (pivot points/consolidation) etc.. it’s like traffic rush hours or / everyone going gym at 6pm or electric use at 12noon etc.. now this chart gets interesting in the mid 5’s ( may be time for a trend reversal) - then what kicks in- What all the longs are talking about here , data, biology, science, trials, treatments, standards of care above and beyond the standards .. trading is good but soon investment will call , hold or put finger on trigger, green button after next leg 🦵 down. ✌️ $BLRX 👀 also

0 · Reply

gargoyl Jan. 28 at 5:41 PM

$BLRX $VSTM one month ago 👇🏼

0 · Reply

gargoyl Jan. 28 at 4:00 AM

$BLRX a year ago, Phil wrote this clarifying, strategic mission, path of action, financially potent letter, directly to us fellow share holders regarding the creation of enduring value to shareholders. They initiated the ”Combat” study w/ Merck in Sept 2016 , some may recall… it’s been a journey.. Re- Reading the promised trusted letter , it seems an inflection point is imminent, it’s just my gut , time will tell , patience is usually rewarded … GenFleet ? Regeneron ? Gloria ? Ayrmid ? Hemispherian AS GLIXI ? Other ? Merck / Sanofi /Pfizer / Novartis St Jude ? Columbia U ? Washington U ? 👇🏼 long the 🦋 🎯 $18 in 2026 $XBI $VSTM $REGN https://ir.biolinerx.com/node/14001/pdf

0 · Reply

KaydenG1 Jan. 25 at 10:35 PM

$BLRX what is everyone thinking with this being down so low postmarket for monday? Continued fall or recovery?

0 · Reply

Smoothopera1or Jan. 24 at 2:16 AM

$BLRX looking bad bruv

1 · Reply

gargoyl Jan. 23 at 11:30 PM

$BLRX BiolineRx is lining her ducks 🦆 ..🦆 …🦆 with S-8 filing, can be useful when hiring 🤔 Long the 🦋

0 · Reply

gargoyl Jan. 23 at 7:32 PM

$BLRX 👀 beast 🦍 incoming $XBI $IBB $VSTM

0 · Reply

gargoyl Jan. 23 at 3:17 PM

$VSTM will again continue down 🔪 $BLRX will 🏃‍♀️ higher $4 near future 👀 👇🏼

0 · Reply

gargoyl Jan. 23 at 2:56 PM

$BLRX 🦍 👀 set up for beast mode … watch .. $VSTM $REGN $XBI

0 · Reply

gargoyl Jan. 23 at 6:41 AM

$BLRX the new trend is economic fundamentals after value as the bull trend broadens into full market, well, add growth to that and you have a perfect trifecta storm on a currently little 🧢 cap. Instinct says the appearance of manipulated weakness is a ruse for accumulation, but only until the second a milestone hits , most likely equivalent to current market cap, the veil be removed and MM can’t shade the demand in the dark pool and a tenuous spread book of wide Bid and Ask. Is today the day , it’s inevitable. Long the 🦋 🎯 $18 $XBI $REGN

0 · Reply

gargoyl Jan. 22 at 4:43 PM

$BLRX pressure cooker mode , w/ $XBI currently exploding leading credence to some smaller cap buyouts , partnerships, catalysts and breakthroughs in treatments .. On the perfect storm of a broader market rising … W/ BiolineRx ‘s pipeline, partnerships, potential milestone triggers and collaborations in SCD, MM , Tumors, apheresis, brain tumors other cancers, not only do we have multiple shots on goal , we are up in score with low float , low market cap and revenue w/ low expenses to boot 🥾.. looking for a consolidation fade into slow walk up , followed by a run 🏃‍♂️ then a pop after a 🦍 beast mode finish.. into 🎯 teens…. 👀

0 · Reply

Market Cap	12.97M
Revenue (ttm)	28.94M
Net Income (ttm)	-9.22M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-31.86%
Debt to Equity Ratio	0.52

Volume	24,968
Avg Vol	22,156
Day's Range	N/A - N/A
Shares Out	4.35M
Stochastic %K	29%
Beta	1.32
Analysts	Strong Sell
Price Target	$20.33